A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer

por Oh, S C, Sur, H Y, Sung, H J, Choi, I K, Park, S S, Seo, J H, Jeen, Y T, Chun, H J, Shin, S W, Mok, Y J, Kim, J S, Kim, Y H
Publicado 2007